Table 3.

Pn prevalence at each time point for each experimental group

	Prevalence before treatment	Fumagillin	Albendazole	Combination	Infected Control
Week 0	44%	38%	50%	38%	50%
Week 5		44%	25%	13%	31%
Week 10		31%	0%	56%	6%
Week 16		14%	44%	15%	40%

The prevalence in the uninfected control group was 0 at all 4 time points and is not included in this table or the overall prevalence calculation. The average Pn prevalence before treatment (week 0) across all groups was 44%. There was no significant interaction between treatment and time point (P = 0.22), or significant main effect of treatment or time point (P = 0.43, P = 0.15, respectively) where a P value < 0.05 was considered significant.